Chelsea Therapeutics International, Ltd.

An advisory committee’s overwhelmingly negative verdict on Biogen, Inc. ’s Aduhelm (aducanumab), coming in the face of a highly positive US Food and Drug Administration review of the Alzheimer's dise

The upcoming advisory committee reviews of the first coronavirus vaccine(s) and Biogen, Inc. ’s aducanumab for Alzheimer’s should be two historic panel meetings. With that in mind, here are some

Many years ago, around the time when the US FDA was considering a “reevaluation” of the erythropoiesis-stimulating agents (ESAs) with a forthcoming advisory committee, the agency's dean of drug develo

Denmark’s CNS specialist H. Lundbeck AS expects to launch its new psychiatric product brexpiprazole in the U.S. in the second half of 2015, a year ahead of expectations. However, this event along